(RPGRIPI), Inosine-5-prime-monophosphate dehydrogenase, type I (IMPDH1 guanine nucleotide binding protein, alpha transducing activity polypeptide 2 (GNAT2), cyclic nucleotide gated channel beta 3 (CNGB3), retinoschisin 1 (Rsl), ocular albinism type 1 (OA1), oculocutaneous albinism type 1 (OCA1) tyrosinase, P21 WAF-1/Cipl, platelet-derived growth factor (PDGF), Endostatin Angiostatin, arylsulfatase B, or 13 -glucuronidase.

20. A composition comprising the AAV virus of claim 14 or viral vector of any of claims 15-19 and a carrier.

21. A pharmaceutical composition comprising the AAV virus of claim 14 or viral vector of any of claims 15-19 and a pharmaceutically acceptable carrier.

22. A cell transduced by or comprising the viral vector of any one of claims 15-19.

23. The cell of claim 22, wherein the cell is a mammalian cell.

24. The cell of claim 23, wherein the cell is a human cell.

25. The cell of claim 23, wherein the cell is a non-human cell.

26. The cell of any one of claims 22-25, wherein the cell is in vitro, optionally wherein the cell is an ocular cell.

27. The cell of any one of claims 22-25, wherein the cell is *in vivo*, optionally wherein the cell is an ocular cell.

28. A viral vector as described by any one of claims 15-19 for use as a medicament or in diagnosis.

29. Use of the viral vector of any one of claims 15-19 in the manufacture of a medicament for the prophylactic or therapeutic treatment of an ocular disease in a mammal wherein the disease is retinitis pigmentosa, maculopathies, Leber's congenital amaurosis, early onset severe retinal dystrophy, achromatopsia, retinoschisis, ocular albinism, oculocutaneous albinism, glaucoma, Stargardt disease, choroideremia, age-related macular degeneration, SCAT, color blindness, or lysosomal storage diseases that affect the cornea, such as MPS IV and MPS VII.

30. A cell as described by any one of claims 22-25 for use as a medicament or in diagnosis.

31. Use of the cell of any one of claims 22-25 in the manufacture of a medicament for the treatment of an ocular disease in a mammal wherein the disease is retinitis pigmentosa, maculopathies, Leber's congenital amaurosis, early onset severe retinal dystrophy, achromatopsia, retinoschisis, ocular albinism, oculocutaneous albinism, glaucoma, Stargardt disease, choroideremia, age-related macular degeneration, SCAT, color blindness, or lysosomal storage diseases that affect the cornea, such as MPS IV and MPS VII.

32. The use of claim 31 wherein the cells used in the manufacture of the medicament comprise retina outer plexiform layer (OPL) cells.